ClinicalTrials.gg
RecruitingNCT07800897Updated Oct 5, 2026

A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants

A Phase 1 interventional study of Navlimetostat and Itraconazole in Healthy Female Adults, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 5, 2026Now RecruitingFirst site in Canada+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants

02

Conditions studied

  • Healthy Female Adults

Keywords

  • PRMT5
  • MTAP
  • MRTX1719
  • MountainTAP
  • Healthy Adult Female
  • Individuals not of childbearing potential
  • Open Label Study
  • Clinical Research Unit
  • Phase 1
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy adult female (as assigned at birth) individuals not of (INOCBP) who have no findings on medical history, physical examination (PE), vital signs (VS), 12-lead (ECGs), or clinical laboratory determinations, as assessed by the investigator.
  • Participants must have a of 18.0 to 35.0 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any significant acute or chronic medical illness (in the assessment of the investigator).
  • Participants must not have a history of prolonged bleeding or excessive bruising.
  • Participants must not have any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Part 1A

    Drug: Navlimetostat · Drug: Itraconazole

  • Experimental
    Part 1B

    Drug: Navlimetostat · Drug: Rifampin

  • Experimental
    Part 2

    Drug: Navlimetostat · Drug: Midazolam

  • Experimental
    Part 3

    Drug: Navlimetostat

  • Experimental
    Part 4

    Drug: Navlimetostat · Drug: Pantoprazole

Interventions

  • Specified dose on specified days

    Also known as: BMS-986504, MRTX-1719

  • DrugItraconazole

    Specified dose on specified days

  • DrugRifampin

    Specified dose on specified days

  • DrugMidazolam

    Specified dose on specified days

  • DrugPantoprazole

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) of Navlimetostat

    Part 1A, Part 1B, Part 3, Part 4

    Time frame: Up to approximately 3 weeks

  2. Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of Navlimetostat

    Part 1A

    Time frame: Up to approximately 3 weeks

  3. (AUC(INF)) of Navlimetostat with the coadministration of itraconazole

    Part 1A

    Time frame: Up to approximately 3 weeks

  4. AUC(INF) of Navlimetostat without the coadministration of itraconazole

    Part 1A

    Time frame: Up to approximately 3 weeks

  5. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Navlimetostat

    Part 1B, Part 3, Part 4

    Time frame: Up to approximately 3 weeks

  6. AUC(INF) of Navlimetostat with the coadministration of Rifampin

    Part 1B

    Time frame: Up to approximately 3 weeks

  7. AUC(INF) of Navlimetostat without the coadministration of Rifampin

    Part 1B

    Time frame: Up to approximately 3 weeks

  8. Cmax of Midazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  9. AUC(0-T) of Midazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  10. AUC(INF) of Midazolam with the coadministration of Navlimetostat

    Part 2

    Time frame: Up to approximately 3 weeks

  11. AUC(INF) of Midazolam without the coadministration of Navlimetostat

    Part 2

    Time frame: Up to approximately 3 weeks

  12. AUC(INF) of Navlimetostat with a high fat meal

    Part 3

    Time frame: Up to approximately 3 weeks

  13. AUC(INF) of Navlimetostat without a high fat meal

    Part 3

    Time frame: Up to approximately 3 weeks

  14. AUC(INF) of Navlimetostat with the coadministration of Pantoprazole

    Part 4

    Time frame: Up to approximately 3 weeks

  15. AUC(INF) of Navlimetostat without the coadministration of Pantoprazole

    Part 4

    Time frame: Up to approximately 3 weeks

  16. Drug-related AEs

    Time frame: Up to approximately 6 weeks

Secondary outcomes

  1. Adverse events (AEs)

    Time frame: Up to approximately 6 weeks

  2. Serious adverse events (SAEs)

    Time frame: Up to approximately 6 weeks

  3. AEs leading to discontinuation of study or study intervention

    Time frame: Up to approximately 6 weeks

  4. Number of participants with clinically significant changes in physical examination (PE)

    Time frame: Up to approximately 6 weeks

  5. Number of participants with clinically significant changes in vital signs (VS)

    Time frame: Up to approximately 6 weeks

  6. Number of participants with clinically significant changes in 12-lead electrocardiograms (ECGs)

    Time frame: Up to approximately 6 weeks

  7. Number of participants with clinically significant changes in clinical laboratory test results

    Time frame: Up to approximately 6 weeks

  8. AUC(0-T) of Navlimetostat

    Part 1A

    Time frame: Up to approximately 3 weeks

  9. Time of maximum observed concentration (Tmax) of Navlimetostat

    Part 1A, Part 1B, Part 3, Part 4

    Time frame: Up to approximately 3 weeks

  10. Half-life (T-HALF) of Navlimetostat

    Part 1A, Part 1B, Part 3, Part 4

    Time frame: Up to approximately 3 weeks

  11. Apparent total body clearance (CLT/F) of Navlimetostat

    Part 1A, Part 1B, Part 3, Part 4

    Time frame: Up to approximately 3 weeks

  12. Apparent volume of distribution at terminal phase (Vz/F) of Navlimetostat

    Part 1A, Part 1B, Part 3, Part 4

    Time frame: Up to approximately 3 weeks

  13. Tmax of Midazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  14. T-HALF of Midazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  15. CLT/F of Midazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  16. Vz/F of Midazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  17. Cmax of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  18. AUC(0-T) of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  19. AUC(INF) of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  20. AUC(0-192) of Navlimetostat Metabolite

    Part 1A

    Time frame: Up to approximately 3 weeks

  21. AUC(0-24) of Navlimetostat Metabolite

    Part 2

    Time frame: Up to approximately 3 weeks

  22. Tmax of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  23. T-HALF of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  24. Mean ratio (MR)_Cmax of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  25. MR_AUC(0-T) of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  26. MR_AUC(INF) of Navlimetostat Metabolite

    Time frame: Up to approximately 3 weeks

  27. MR_AUC(0-192) of Navlimetostat Metabolite

    Part 1A

    Time frame: Up to approximately 3 weeks

  28. MR_AUC(0-24) of Navlimetostat Metabolite

    Part 2

    Time frame: Up to approximately 3 weeks

  29. Cmax of Rifampin

    Part 1A and Part 1B

    Time frame: Up to approximately 3 weeks

  30. Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of Rifampin

    Part 1A and Part 1B

    Time frame: Up to approximately 3 weeks

  31. Trough observed concentration (Ctrough) of Rifampin

    Part 1A and Part 1B

    Time frame: Up to approximately 3 weeks

  32. Tmax of Rifampin

    Part 1A and Part 1B

    Time frame: Up to approximately 3 weeks

  33. Cmax of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  34. AUC(0-T) of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  35. AUC(INF) of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  36. Tmax of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  37. T-HALF of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  38. MR_Cmax of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  39. MR_AUC(0-T) of 1-hydroxymidazolam

    Part 2

    Time frame: Up to approximately 3 weeks

  40. MR_AUC(INF) of 1-hydroxymidazolam with the coadministration of Navlimetostat

    Part 2

    Time frame: Up to approximately 3 weeks

  41. MR_AUC(INF) of 1-hydroxymidazolam without the coadministration of Navlimetostat

    Part 2

    Time frame: Up to approximately 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 2, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Mar 25, 2027
CompletionEst.
Mar 25, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
1 site added — first site in Canada
Show site
  • Syneos Health Clinique; Inc. · Québec, Canada
Oct 5, 2026
Start date
Aug 26, 2026→Aug 31, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Canada
    Show site
    • Syneos Health Clinique; Inc. · Québec, Canada
    Start date Aug 26, 2026→Aug 31, 2026 (now actual)
    + 3 other changes: verification date, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07800897
Responsible party
Sponsor
First posted
Sep 2, 2026
Start date
Aug 31, 2026
Primary completion
Mar 25, 2027 (estimated)
Completion
Mar 25, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion